Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Pulmonary Disease, Chronic Obstructive 1Pneumonia 1Colonic Neoplasms 1

Interventions

Methylprednisolone 3Bronchoscopy 2Bronchoalveolar Lavage 2Blood Specimen Collection 2ziprasidone 1pirfenidone 1ceftolozane, tazobactam drug combination 1Zolpidem 1XAV-19 1X-Rays 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Ultrasonography 1Tranexamic Acid 1Tobramycin 1Thoracotomy 1Thoracic Surgery, Video-Assisted 1Surveys and Questionnaires 1Standard of Care 1Spironolactone 1Sodium Bicarbonate 1Sevelamer 1Saline Solution 1Rocuronium 1Ribavirin 1Prednisone 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pneumonia × CIMAvax EGF × Clear all
NCT04298606 2026-03-17

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡